Owlstone Medical won up to $49.1 million from ARPA‑H to develop an at‑home, over‑the‑counter multi‑cancer breath test capable of detecting 30+ cancers at early stages — a program aimed at rapid, decentralized screening modalities. The award backs translational work to bring volatile-biomarker panels and consumer diagnostics toward clinical validation and scale. Separately, startup Countable Labs unveiled a 10‑color single‑tube PCR platform that partitions reactions into 30 million gel compartments and reads outputs with light‑sheet microscopy, aiming to bridge digital PCR and sequencing for high‑plex, compact assays. Together these moves highlight continued investment in high‑throughput, point‑of‑care and population screening diagnostics.